Cohance Lifesciences Limited (NSE:COHANCE)
India · Delayed Price · Currency is INR 425.25
-0.05 (-0.01%)
Jul 31, 2026, 3:30 PM IST
Cohance Lifesciences Market Cap
Cohance Lifesciences has a market cap or net worth of 162.61 billion as of July 31, 2026. Its market cap has decreased by -57.38% in one year.
Market Cap
162.61B
Enterprise Value
164.58B
Revenue
22.69B
Ranking
n/a
PE Ratio
90.82
Stock Price
425.25
ChartMarket Cap Chart
Since March 9, 2020, Cohance Lifesciences's market cap has increased from 33.71M to 162.61B, an increase of 482,351.16%. That is a compound annual growth rate of 276.52%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 31, 2026 | 162.61B | -19.59% |
| Dec 31, 2025 | 202.22B | -30.24% |
| Dec 31, 2024 | 289.89B | 57.55% |
| Dec 29, 2023 | 184.00B | 46.05% |
| Dec 30, 2022 | 125.98B | 0.33% |
| Dec 31, 2021 | 125.56B | 9.05% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Mar 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Emcure Pharmaceuticals | 371.61B |
| Wockhardt | 318.44B |
| Piramal Pharma | 259.61B |
| Eris Lifesciences | 187.72B |
| NATCO Pharma | 164.24B |
| Alembic Pharmaceuticals | 156.67B |
| Alivus Life Sciences | 142.38B |
| Akums Drugs and Pharmaceuticals | 100.79B |